ArticleMicrobial cell factories2003
The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi.
Article in Microbial cell factories, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- An integrated cell and medium engineering approach for production of a nanobody fusion in Saccharomyces cerevisiae.Applied microbiology and biotechnology · 2026Article
- Harnessing the potential of microalgae for the production of monoclonal antibodies and other recombinant proteins.Protoplasma · 2024Review
- A fast, ultrasensitive SERS immunoassay to detect SARS-CoV-2 in saliva.Analytica chimica acta · 2022Article
- Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective.Biophysical reviews · 2022Review
- A comprehensive comparison between camelid nanobodies and single chain variable fragments.Biomarker research · 2021Review
- Effects of variable domain orientation on anti-HER2 single-chain variable fragment antibody expressed in the Escherichia coli cytoplasm.Biotechnology progress · 2021Article
- Designing and generating a single-chain fragment variable (scFv) antibody against IL2Rα (CD25): AnIranian journal of basic medical sciences · 2021Article
- Functional production of human antibody by the filamentous fungusFungal biology and biotechnology · 2020Article
- Design and Production of Bispecific Antibodies.Antibodies (Basel, Switzerland) · 2019Review
- David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments.Antibodies (Basel, Switzerland) · 2019Review
- Homologous alignment cloning: a rapid, flexible and highly efficient general molecular cloning method.PeerJ · 2018Article
- Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy.BioMed research international · 2018Review
- Applying Unconventional Secretion in Ustilago maydis for the Export of Functional Nanobodies.International journal of molecular sciences · 2017Article
- A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting.PloS one · 2017Article
- Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs.Microbial cell factories · 2015Review
- Single Chain Variable Fragments Produced in Escherichia coli against Heat-Labile and Heat-Stable Toxins from Enterotoxigenic E. coli.PloS one · 2015Article
- Refolded scFv antibody fragment against myoglobin shows rapid reaction kinetics.International journal of molecular sciences · 2014Article
- Microbials for the production of monoclonal antibodies and antibody fragments.Trends in biotechnology · 2014Review
- High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli.Microbial cell factories · 2013Article
- Expression of recombinant antibodies.Frontiers in immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review we will focus on the current status and views concerning the production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. We will focus on single-chain antibody fragment production (scFv and VHH) by these lower eukaryotes and the possible applications of these proteins. Also the coupling of fragments to relevant enzymes or other components will be discussed. As an example of the fusion protein strategy, the 'magic bullet' approach for industrial applications, will be highlighted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.